Minerva Neurosciences Inc NERV 深 沪
交易中 07-21 11:50:34 美东时间
4.27
-0.100
-2.29%
华盛通- 最 高4.36
- 今 开4.36
- 成交量 2.12万股
- 最 低 4.24
- 昨 收 4.37
- 总市值 1.99亿
- 52周最高 12.46
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 1.76
- 委 比 -32.76%
- 总股本 4658.87万
- 历史最高 126.72
- 量 比 0.38
- 振 幅 2.75%
- 历史最低 1.15
- 每 手 1
- 风险率 1.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia
Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia Minerva Neurosciences highlighted roluperidone as a potential first treatment targeting primary negative symptoms of schizophrenia, an area with no FDA-approved therapies. Confirmatory Phase
06-05 19:28
Minerva Neurosciences Launches ATM Offering to Fund Trial
Minerva Neurosciences ( ($NERV) ) has shared an announcement. On May 27, 2026, ...
05-28 05:25
Minerva Neurosciences To Offer Up To $75M In Common Stock Offering
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001598646/000119312526241930/d119518d8k.htm
05-28 04:51
Minerva Neurosciences Q1 Adj. EPS $(0.17) Misses $(0.13) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 66 percent increase over losses of $(0.50) per share
05-05 20:17
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Citizens Initiates Coverage On Minerva Neurosciences with Market Outperform Rating, Announces Price Target of $14
Citizens analyst Jason N. Butler initiates coverage on Minerva Neurosciences (NASDAQ:NERV) with a Market Outperform rating and announces Price Target of $14.
04-15 21:18
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
Minerva Neurosciences ( ($NERV) ) just unveiled an update. Minerva Neuroscience...
04-07 05:48
Minerva Announces Leadership Transition
Minerva Neurosciences announced that Jim O’Connor is appointed as Chief Business Officer and General Counsel, succeeding Geoff Race, who is leaving the company but will remain as a consultant. Mr. Race has been instrumental in shaping the company over his 16 years with Minerva. Dr. Remy Luthringer praised Mr. Race's leadership and expressed confidence in Mr. O’Connor’s ability to advance the company, especially with roluperidone’s upcoming Phase ...
04-02 20:05
快讯 | Minerva Neurosciences 宣布在全球三期确证性试验中，第一名患者已开始接受 Roluperidone 治疗精神分裂症阴性症状的筛查。
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confir...
04-01 04:05
Minerva Neurosciences Reveals Data From Its Open-Label Safety Trial Evaluating Roluperidone Co-Administered With Olanzapine At SIRS 2026; Trial Demonstrated No Safety Concerns When Co-Administering Roluperidone And Olanzapine
BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system
03-26 04:13
